|
Vice President of Aureon Laboratories to Present at GTCbio’s 2nd Rediscovering Biomarkers Conference on July 10-11
Peter Duncan, Vice President of Aureon Laboratories to Present at GTCbio’s 2nd Rediscovering Biomarkers Conference on July 10-11, 2008 in Boston, MA
 Print View
April 24, 2008 (FPRC) -- Peter Duncan, Vice President at Aureon Laboratories will be presenting at GTCbio’s 2nd Annual Rediscovering Biomarkers Conference on July 10-11, 2008 in Boston, MA. Dr. Duncan will speak on “Aureon Systems Pathology: A Novel Platform for Automated Tissue Biomarker Quantitation.”
Aureon has created a state of the art tissue analysis platform, called Systems Pathology. Systems Pathology establishes a comprehensive biometric signature that takes into account molecular biomarkers, tissue morphometry, and clinical phenotypes, and assigns a single score for individual patient risk. Aureon have applied this platform to the development and validation of two commercially available tests for men with prostate cancer: 1) Prostate Px® assesses an individual’s risk of clinical failure utilizing prostatectomy specimens 2) Prostate PxÅ® assesses an individual’s risk of clinical failure utilizing diagnostic needle biopsy specimens.
Aureon’s approach has further utility for pre-clinical, translational, and clinical development of solid tumor cancer therapeutics. Aureon's morphometric image analysis platform extracts hundreds of statistical measurements, called "features," from hematoxylin and eosin (H&E) and immunofluorescence (IF) stained FFPE tissue. Morphometric image analysis of H&E stained tissue provides quantitative in situ analysis of the histological attributes of tissue. Morphometric image analysis of multiplexed IF assays provides quantitative in situ analysis of cell-type specific location and quantity of protein biomarkers. In short, Systems Pathology offers a quantitative, integrated, “high definition” alternative to standard pathology techniques.
Aureon Systems Pathology is currently being utilized by their academic and industry partners in the following areas: Pharmacodynamic studies, molecular pathway analysis studies, retrospective and prospective analysis of patient tissue samples for better trial randomization, prediction of therapeutic responders, development of companion prognostics.
The 2nd Annual Rediscovering Biomarkers Conference will exposes attendees to the latest advancements and developments in biomarkers and predictive medicine. Attendees will gain insight into discovery and development processes, hear about new biomarkers and upcoming trends in the industry, as well as the status of those in clinical trials. Delegates will also receive highly valuable information on tools for improving reimbursement strategies and the efficacy and validation of biomarkers.
For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/conferenceDetails.aspx?id=124
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com
Send an email to Rania Hafez of GTCbio
(626) 256-6405
Keywords:
biomarkers
|
